Heart Failure Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations.
“Heart Failure Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Heart Failure Pipeline Report:
Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years. Heart Failure Key players such as – GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Asklepios Biopharmaceutical, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment
Heart Failure Emerging therapies such as – GSK3884464, LY 3461767, JK07, NAN-101, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.
In June 2019, The Food and Drug Administration (FDA) granted Orphan Drug designation to Revascor (rexlemestrocel-L; Mesoblast), a potential therapy for the prevention of post-implantation mucosal bleeding in end-stage chronic heart failure patients who require a left ventricular assist device (LVAD)
In May 2020 Mesoblast, Inc. completed a trial which was initiated in February 2014, the trial titled “Double-blind, Randomized, Sham procedure-controlled, parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells(Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1”
Heart Failure Pipeline Therapeutics Assessment
Heart Failure Assessment by Product Type
Heart Failure By Stage and Product Type
Heart Failure Assessment by Route of Administration
Heart Failure By Stage and Route of Administration
Heart Failure Assessment by Molecule Type
Heart Failure by Stage and Molecule Type
DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:
GSK3884464: GlaxoSmithKline
LY 3461767: Eli Lilly and Company
JK07: Salubris Biotherapeutics
NAN-101: Asklepios Biopharmaceutical
HS-001: Heartseed Inc.
SRD-001: Sardocor Corp.
hiPSC-CM therapy: Help Therapeutics
Mavacamten: Bristol Myers Squibb
HU 6: Rivus Pharmaceuticals
PL 3994: Palatin Technologies
AZD9977: AstraZeneca
Rexlemestrocel-L: Mesoblast
Finerenone: Bayer
Tirzepatide: Eli Lilly and Company
Heart Failure Pipeline Analysis:
The Heart Failure pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the Heart Failure treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies
Heart Failure Pipeline Market Drivers
Biomarkers helps in understanding the complexity of heart failure
Recent advancements in research and development
Rising geriatric population
Heart Failure Pipeline Market Barriers
Lack of therapies for HFpEF and acute heart failure
High annual cost
Long time duration to measure the Clinical trial endpoints
Get a Free Sample PDF Report to know more about Heart Failure Pipeline Assessment
Scope of Heart Failure Pipeline Drug Insight
Coverage: Global
Key Heart Failure Companies: GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Asklepios Biopharmaceutical, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others
Key Heart Failure Therapies: GSK3884464, LY 3461767, JK07, NAN-101, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others
Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers
Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials
Table of Contents
1
Heart Failure Report Introduction
2
Heart Failure Executive Summary
3
Heart Failure Overview
4
Heart Failure- Analytical Perspective In-depth Commercial Assessment
5
Heart Failure Pipeline Therapeutics
6
Heart Failure Late Stage Products (Phase II/III)
7
Heart Failure Mid Stage Products (Phase II)
8
Heart Failure Early Stage Products (Phase I)
9
Heart Failure Preclinical Stage Products
10
Heart Failure Therapeutics Assessment
11
Heart Failure Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Heart Failure Key Companies
14
Heart Failure Key Products
15
Heart Failure Unmet Needs
16
Heart Failure Market Drivers and Barriers
17
Heart Failure Future Perspectives and Conclusion
18
Heart Failure Analyst Views
19
Appendix
20
About DelveInsight
Download Sample PDF Report to know more about Heart Failure drugs and therapies
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
